Holen Sie sich die Stockscreener-App
29.40
4.27%
-1.31
Handel nachbörslich:
29.40
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Slides Ahead of San Diego Concference - Baystreet.ca
Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025 - TipRanks
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 - The Manila Times
Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data - Stock Titan
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq
Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Xenon Pharmaceuticals Advances Clinical Pipeline Amid Financial Losses - TipRanks
Xenon Pharmaceuticals reports Q4 EPS (84c), consensus (84c) - TipRanks
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Xenon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenon Pharmaceuticals Q4 Net Loss Widens -February 27, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88 - Marketscreener.com
Xenon Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:20 pm EST - Marketscreener.com
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update - The Manila Times
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):